DLL4 and neoplasm: REGN421 (enoticumab) is a human IgG1 monoclonal antibody, which can inhibit the Notch signal pathway via binding to DLL4; it was observed to inhibit tumor growth by the formation of non-functional capillaries in ovarian tumor xenograft models.